A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
← catalyst calendarSponsored by Alumis Inc (industry) · ALMS — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
862actual
Sites
124
Countries
Austria, Canada, Estonia +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-20 | actual | When the study began enrolling |
| Primary completion | 2025-09-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-18 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: Envudeucitinib
- Drug: Placebo
- Drug: Apremilast
Primary outcome
what the primary-completion date above is the date OFTo determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo
measured 16 weeks
Permalink · ALMS's whole pipeline · Catalyst calendar · Every registered study · What changed